オプションチェーンは、Nano Labsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Nano Labsの市場センチメントを評価します。.

Nano Labs (NASDAQ:NA) 株価情報, オプションチェーン

Nano Labs

Nano Labs Ltd operates as a fabless IC design company and product solution provider in China. It engages in the development of HTC chips, HPC chips, distributed computing and storage solutions, smart-NICs, vision computing chips, and distributed rendering. Its products comprise Cuckoo 1.0 Chip, Cuckoo 2.0 Chip, and Darkbird 1.0 Chip. Majority of the company revenue comes from China.

Nano Labs Ltd

NaaS Technology Inc. - American Depositary Shares

Naas Technology Inc

N-able Inc

Nabox

NATL AUSTRALIA BK S/ADR by National Australia Bank Ltd. (Victoria, Australia)

National Australia Bank Ltd

Nuveen California Quality Municipal Income Fund

NATIONAL CAP BANCORP INC by NATIONAL CAP BANCORP INC.

National Cap Bancorp Inc

Impact Shares Trust I Impact Shares NAACP Minority Empowerment ETF

NextPoint Financial Inc Ordinary Shares

NEXTPOINT FINANCIAL INC by NextPoint Financial Inc.

NextPoint Financial Inc

Nuveen Quality Municipal Income Fund Common Stock

Nuveen Quality Municipal Income Fund

NORTH AMER DATACOM INC by North American DataCom, Inc.

North American DataCom Inc

AMUNDI NASDAQ-100 II UCITS DIST ETF

NATIONAL ART EXCHANGE INC by National Art Exchange, Inc.

NORTH AMERICA FRAC SAND by North America Frac Sand, Inc.

North America Frac Sand Inc

Nafter

NAGA GROUP AG by The Naga Group AG

NEW ASIA HOLDINGS INC by New Asia Holdings, Inc.

New Asia Holdings Inc

Natural Alternatives International, Inc. - Common Stock

Natural Alternatives International Inc

Direxion Daily Homebuilders & Supplies Bull 3X Shares

NORTH ATLNTC SMLLR CO I/T by North Atlantic Smaller Companies Investment Trust Plc.

Northern Dynasty Minerals, Ltd. Common Stock

Northern Dynasty Minerals Ltd

NALU MEDICAL, INC

Jinxin Technology Holding Co

Namib Minerals

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma Co NV

NewAmsterdam Pharma Company N.V. - Warrant

AMND MSCI NA ETF

NORTH AMER EXPL CORP by North American Exploration Corp.

North American Exploration Corp

Nuveen New York Quality Municipal Income Fund Common Stock

Nuveen New York Quality Municipal Income Fund

Series Portfolios Trust Unusual Whales Subversive Democratic Trading ETF

NAN HAI CORP LTD ORD by Nan Hai Corp., Ltd.

NAN HAI CORP LTD UNSP/ADR by Nan Hai Corp., Ltd.

NANJCOIN

Nano - United States Dollar

SPDR S&P North American Natural Resources ETF

NANOPHASE TECHS CORP by Nanophase Technologies Corp.

Nanophase Technologies Corp

NAN YA PCB CORP by Nan Ya Pcb Corp.

NanoVibronix Inc

The Duckhorn Portfolio, Inc. Common Stock

The Duckhorn Portfolio Inc

Innovator Growth-100 Power Buffer ETF - April

Naspers Ltd

Inari Medical Inc

NAGOYA RAILROAD CO ORD by Nagoya Railroad Co. Ltd.

Nagoya Railroad Co Ltd

Nebulas

NASB Financial Inc

AMND NASDAQ 100 ETF

Navios South American Logistics Inc

NAPLES SOAP COMPANY INC by Naples Soap Company Inc.

Naples Soap Co Inc

ISH NASDAQ XAMS ETF

NORTH ASIA STRATEGC HLDGS by North Asia Strategic Holdings Ltd

North Asia Strategic Holdings Ltd

Nordic American Tankers Limited Common Stock

Nordic American Tankers Ltd

Nathan's Famous Inc

National Instruments Corp. Com.

NATIONAL ATOMIC S/GDR by NATIONAL ATOMIC CO KAZATOMPROM JSC

National Atomic Co Kazatomprom JSC

NCR Atleos Corp

FUTURE OF DEFENCE UCITS USD ACC ETF

Themes Transatlantic Defense ETF

Nature's Sunshine Products, Inc. - Common Stock

Natures Sunshine Products Inc

NORTH AMER TUNGSTEIN CRP by North American Tungsten Corporation Ltd.

North American Tungsten Corp Ltd

NORDIC AMERICAN TANKERS ORD

NATL AUSTRALIA BK LTD ORD by National Australia Bank Ltd. (Victoria, Australia)

Nevgold Corp

Innovator ETFs Trust Innovator Growth-100 Power Buffer ETF - August

NATL AMER UNIVERSITY HLDG by National American University Holdings, Inc.

National American University Holdings Inc

Nautilus Biotechnology, Inc. - Common Stock

Nautilus Biotechnology Inc

Navcoin

NAVIDEA BIOPHARMS INC by Navidea Biopharmaceuticals, Inc.

Navidea Biopharmaceuticals Inc

Navient Corp

NAVF PLC by NAVF PLC

NAYA Biosciences

Nuveen Arizona Quality Municipal Income Fund Common Stock

Nuveen Arizona Quality Municipal Income Fund

News

Insider Trades

OSCR

Oscar Health Form 4 Filing Shows Co-Founder Joshua Kushner Bought 1,055,478 Shares At An Average Price Of $13.67/Share

RBC Capital analyst Matthew Hedberg maintains CyberArk Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>) with a Outperform and raises the price target from $328 to $358.

Price Target

Analyst Ratings

CYBR

RBC Capital Maintains Outperform on CyberArk Software, Raises Price Target to $358

Goldman Sachs analyst Ryan Nash maintains UWM Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UWMC#NYSE">UWMC</a>) with a Neutral and lowers the price target from $8.5 to $7.5.

UWMC

Goldman Sachs Maintains Neutral on UWM Hldgs, Lowers Price Target to $7.5

General Motors Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) is recalling over 539,000 vehicles due to two separate transmission-related issues, according to the National Highway Traffic Safety Administration.
Based on information from the NHTSA, Reuters reported that one of the recalls involved 77,824 Chevrolet Express and GMC Savana models from 2022-2023 due to incorrect software in the transmission control module.
The faulty software may result in unintended vehicle movement, reduced power, sudden deceleration, or rear-wheel lockup, significantly increasing the crash risk.
Also Read: <a target="_blank" href="https://www.benzinga.com/tech/24/11/41932481/gm-unveils-2026-cadillac-vistiq-electric-suv-with-starting-price-below-tesla-model-x-lucid-gravity" rel="noreferrer noopener">GM Unveils 2026 Cadillac Vistiq Electric SUV With Starting Price Below Tesla Model X, Lucid Gravity</a>
The report noted that another recall affects 461,839 vehicles, including 2020-2022 Chevrolet Silverado, 2021 Cadillac Escalade, GMC Sierra, Chevrolet Tahoe, and GMC Yukon models, due to a faulty transmission control valve that could cause a rear-wheel lockup.
GM will provide a free software update to fix the issue and implement a special coverage program for vehicles with defective control valves. Dealers have been ordered to stop delivering the affected vehicles immediately.
In the first week of November, General Motors <a target="_blank" href="https://www.benzinga.com/news/24/11/41746228/gm-recalls-107-bolt-electric-vehicles-due-to-fire-risks" rel="noreferrer noopener">recalled 107 Chevrolet Bolt EV and EUV vehicles </a>from 2020-2022 due to fire risks, according to the NHTSA. The vehicles had previously received diagnostic software, but incorrect installation could have led to battery fires at full charge.
Price Action: GM shares traded higher by 2.44% at $59.12 at the last check Thursday.
Image via Shutterstock
Also Read:
<ul>
<li><a href="https://www.benzinga.com//node/41973501" target="_blank" rel="noreferrer noopener">Tesla&#8217;s Profit Power Vs. Rivian&#8217;s Cash Burn: Can The Gap Be Narrowed?</a></li>
</ul>

Equities

Media

General Motors Faces Recall Crisis With Faulty Transmissions: Details

RBC Capital analyst Gregory Renza reiterates Fulcrum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULC#NASDAQ">FULC</a>) with a Sector Perform and maintains $4 price target.

Reiteration

FULC

RBC Capital Reiterates Sector Perform on Fulcrum Therapeutics, Maintains $4 Price Target

Goldman Sachs analyst Eric Sheridan maintains Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) with a Buy and raises the price target from $430 to $490.

SPOT

Goldman Sachs Maintains Buy on Spotify Technology, Raises Price Target to $490

Canaccord Genuity analyst Brian McNamara maintains YETI Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YETI#NYSE">YETI</a>) with a Hold and maintains $44 price target.

YETI

Canaccord Genuity Maintains Hold on YETI Holdings, Maintains $44 Price Target

Goldman Sachs analyst Will Nance maintains Shift4 Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>) with a Buy and raises the price target from $106 to $119.

FOUR

Goldman Sachs Maintains Buy on Shift4 Payments, Raises Price Target to $119

RBC Capital analyst Jimmy Shan maintains Minto Apartment (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MI#TSX">MI</a>) with a Outperform and lowers the price target from C$21.5 to C$20.5.

TSX:MI

TSX:MI/UN

RBC Capital Maintains Outperform on Minto Apartment, Lowers Price Target to C$20.5

Trading Ideas

PXDT

Pixie Dust Technologies Shares Halted On Circuit Breaker To The Upside, Stock Now Up 108.9%

Goldman Sachs analyst Mike Niehuser maintains Nu Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>) with a Buy and raises the price target from $17 to $19.

Goldman Sachs Maintains Buy on Nu Holdings, Raises Price Target to $19

Canaccord Genuity analyst John Newman maintains BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) with a Buy and maintains $171 price target.

BNTX

Canaccord Genuity Maintains Buy on BioNTech, Maintains $171 Price Target

RBC Capital analyst Douglas Miehm reiterates Oncolytics Biotech (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ONC#TSX">ONC</a>) with a Outperform and maintains C$6 price target.

ONCY

TSX:ONC

RBC Capital Reiterates Outperform on Oncolytics Biotech, Maintains C$6 Price Target

Exxon Mobil Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) shares are trading higher by roughly 5% during November after Donald Trump's win in the <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41772701/trumps-historic-return-7-ways-his-second-term-could-impact-the-us-economy">presidential election</a>, as investors anticipate a more favorable regulatory and economic environment for the oil and gas sector.
Trump's administration is expected to prioritize fossil fuel production, potentially reversing recent policies on environmental restrictions and supporting domestic energy expansion, which could directly benefit Exxon's extensive U.S. operations. 
Trump's stance on reducing regulations in the energy sector could make it easier and more cost-effective for Exxon to expand drilling projects, especially in U.S. shale regions like the Permian Basin, where the company has invested heavily in recent years.
Read Also: <a href="https://www.benzinga.com/tech/24/11/41973572/ray-dalios-bridgewater-cuts-stake-in-microsoft-stock-by-20-is-big-tech-losing-its-shine">Ray Dalio&#8217;s Bridgewater Cuts Stake In Microsoft Stock By 20% – Is Big Tech Losing Its Shine?</a>
What To Know: One anticipated shift under Trump's policies would be a rollback of regulations tied to carbon emissions, methane leaks, and drilling permits, which had increased compliance costs for companies like Exxon. 
With eased regulatory pressures, Exxon would have greater flexibility to explore and develop new oil and gas fields without facing stringent environmental compliance costs, potentially boosting production levels and profitability. 
Additionally, Trump's proposal to withdraw from the Paris Climate Agreement and possibly undo green energy subsidies could slow the U.S. transition to renewables, extending the market dominance of traditional energy sources where Exxon is well-positioned.
Read Also: <a href="https://www.benzinga.com/24/11/41971559/disneys-q4-boosted-by-streaming-gains-strong-box-office-and-solid-parks-performance">Disney Q4 Earnings: Revenue And Profit Beat, Best Film Studio Performance, 3-Year Outlook And More</a>
What Else: Trump's protectionist trade policies, particularly his advocacy for tariffs on foreign imports, could also play a role in shaping Exxon's strategy. 
While higher tariffs could increase costs for some imported materials used in refining and exploration, the overarching goal to strengthen domestic energy independence aligns with Exxon's core U.S. operations. 
Furthermore, Trump's inclination to ease sanctions on certain countries, such as Russia, could create new avenues for Exxon to partner in international projects, a potential growth area constrained by recent sanctions.
While uncertainties remain in the global oil market, Trump's commitment to bolstering fossil fuel production and easing regulatory constraints provides an optimistic outlook for Exxon's growth trajectory, making the stock an appealing choice for energy investors post-election.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41971830/producer-inflation-rises-more-than-expected-in-october-should-traders-rethink-interest-rate-cut-path">Producer Inflation Rises More Than Expected In October: Should Traders Rethink Interest Rate Cut Path?</a>
<h2 class="wp-block-heading">How To Buy XOM Stock</h2>
By now you're likely curious about how to participate in the market for Exxon Mobil &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
In the the case of Exxon Mobil, which is trading at $121.61 as of publishing time, $100 would buy you 0.82 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, XOM has a 52-week high of $126.34 and a 52-week low of $95.77.

What's Going On With Exxon Mobil (XOM) Stock?

Goldman Sachs analyst Mark Delaney maintains Luminar Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAZR#NASDAQ">LAZR</a>) with a Sell and lowers the price target from $0.75 to $0.5.

LAZR

Goldman Sachs Maintains Sell on Luminar Technologies, Lowers Price Target to $0.5

Salesforce Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) is aggressively embracing AI in enterprise software. CEO Marc Benioff is positioning the company&#8217;s AI agents as the industry&#8217;s next significant evolution.
The company plans to deploy software bots that can handle various tasks autonomously, aiming to streamline operations and reduce the workload for human employees.
Also Read: <a target="_blank" href="https://www.benzinga.com/top-stories/24/10/41428765/microsoft-salesforce-battle-heats-up-as-ai-agent-technology-takes-center-stage" rel="noreferrer noopener">Microsoft, Salesforce Battle Heats Up As AI Agent Technology Takes Center Stage</a>
During a recent episode of the Equity podcast, Benioff shared his vision, underscoring how this shift could reshape enterprise software as we know it.
Benioff emphasized the potential of these AI agents to revolutionize productivity by extending workforce capabilities without limitations, TechCrunch <a target="_blank" href="https://techcrunch.com/podcast/marc-benioff-says-its-crazy-talk-that-ai-will-hurt-salesforce-wants-a-billion-ai-agents-in-a-year/" rel="noreferrer noopener">reports</a>.
The Salesforce chief noted that hundreds of companies already leverage <a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41607435/salesforce-launches-agentforce-redefining-ai-in-business-with-autonomous-solutions" rel="noreferrer noopener">the Agentforce platform</a>, an AI-driven tool enabling autonomous task execution across business functions.
He set an ambitious target of deploying a billion AI agents within a year, showcasing this technology&#8217;s scalability and market demand.
Benioff shared a personal example from a recent visit to a Disney park, using the company&#8217;s virtual tour guide feature. The AI agent analyzed historical ride preferences and current park traffic, suggesting customized itineraries.
This personalized approach demonstrated how AI can enhance user experiences across different sectors, including entertainment, retail, and healthcare.
While Salesforce continues to develop its Agentforce platform, Benioff criticized Microsoft Corp&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) AI offerings and expressed skepticism about Microsoft&#8217;s Copilot agents. He cited user complaints and research indicating security and functionality issues with Microsoft&#8217;s solutions.
Despite the rise of new AI-focused startups, Benioff remains confident in Salesforce&#8217;s position.
Benioff emphasized that Salesforce&#8217;s secure data infrastructure sets it apart, enabling more reliable AI-driven insights and services.
As part of its growth strategy, Salesforce uses its own AI agents internally across various departments, including customer service and sales.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14093208/newplot-8.png" alt="" class="wp-image-648092" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14093208/newplot-8.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14093208/newplot-8-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
Northland Capital Partners said Salesforce&#8217;s AgentForce platform <a target="_blank" href="https://www.benzinga.com/top-stories/24/10/41145130/salesforces-genai-platform-agentforce-on-par-with-microsoft-analyst" rel="noreferrer noopener">is &#8220;on par&#8221; with</a> Microsoft.
Jim Cramer, host of CNBC&#8217;s &#8220;Mad Money,&#8221; praised Salesforce for its <a target="_blank" href="https://www.benzinga.com/markets/equities/24/11/41890694/jim-cramer-says-salesforce-agentforce-is-the-best-use-of-ai-he-has-seen-makes-sense-that-the-stock-has-gone-up-so-much" rel="noreferrer noopener">innovative AI product</a>, Agentforce, crediting the tool for driving the recent surge in the company&#8217;s stock.
Cramer shared his views on X, describing Agentforce as &#8220;pretty revolutionary.&#8221; He pointed out that the stock&#8217;s upward movement aligns with the impact of this cutting-edge AI solution and highlighted it as the most effective AI use case he has seen, validating the stock&#8217;s rally.
Salesforce&nbsp;stock surged over 33% year-to-date. Investors can gain exposure to the stock through SPDR Select Sector Fund &#8211; Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) and Vanguard Total Stock Market ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTI#NYSE">VTI</a>).
Price Action: CRM stock is down 2.18% at $334.28 at the last check on Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/41971559/disneys-q4-boosted-by-streaming-gains-strong-box-office-and-solid-parks-performance" target="_blank" rel="noreferrer noopener">Disney Q4 Earnings: Revenue And Profit Beat, Best Film Studio Performance, 3-Year Outlook And More</a></li>
</ul>
Photo by NYCStock via Shutterstock

Management

Tech

MSFT

Salesforce CEO Marc Benioff Bets Big on Billion Bots

Canaccord Genuity analyst Sumant Kulkarni maintains Zevra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVRA#NASDAQ">ZVRA</a>) with a Buy and lowers the price target from $25 to $23.

ZVRA

Canaccord Genuity Maintains Buy on Zevra Therapeutics, Lowers Price Target to $23

RBC Capital analyst Michael Harvey reiterates Peyto Exploration &amp; Dev (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PEY#TSX">PEY</a>) with a Sector Perform and maintains C$17 price target.

TSX:PEY

RBC Capital Reiterates Sector Perform on Peyto Exploration & Dev, Maintains C$17 Price Target

Goldman Sachs analyst Ryan Nash maintains loanDepot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDI#NYSE">LDI</a>) with a Sell and raises the price target from $1.7 to $2.7.

Goldman Sachs Maintains Sell on loanDepot, Raises Price Target to $2.7

On Thursday, Immutep Limited&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMMP#NASDAQ">IMMP</a>) released data from the INSIGHT-003 Phase 1 trial of eftilagimod alpha (efti) in combination with Merck &amp; Co Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Keytruda (pembrolizumab) and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41970785/immuteps-efti-shows-excellent-survival-data-from-insight-003-trial-in-non-small-cell-lung-cancer" rel="noreferrer noopener">cancer (1L NSCLC) patients</a>.
The survival data as of data cutoff of Oct. 15 from the triple combination therapy in patients irrespective of PD-L1 expression with a minimum followup of 22 months (N=21) shows:
<ul>
<li>Median Overall Survival (OS) of 32.9 months.</li>
<li>Median Progression-Free Survival (PFS) of 12.7 months.</li>
<li>24-month Overall Survival (OS) of 81.0%.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39747049/australia-based-cancer-focused-immuteps-lead-cancer-drug-shows-meaningful-response-in-untreated-h" rel="noreferrer noopener">Australia Based Cancer Focused Immutep&#8217;s Lead Cancer Drug Shows &#8216;Meaningful Response&#8217; In Untreated Head &amp; Neck Cancer, Stock Soars</a>
The company compares the data with the 22.0-month median OS, 9.0-month median PFS, and 24-month OS rate of 45.5% from a registrational trial of anti-PD-1 and doublet chemotherapy in non-squamous 1L NSCLC regardless of PD-L1 expression.
Marc Voigt, CEO of Immutep, said, &#8220;The overall survival and progression-free survival data from this mature cohort of patients in INSIGHT-003 with nearly a 2-year minimum followup exceeds our expectations.&#8221;
Data from all evaluable patients to date (N=40) demonstrates significant improvement in Overall Response Rate (ORR) across all levels of PD-L1 expression compared to historical control:
<ul>
<li>75.0% ORR versus 62.1% ORR in patients with high PD-L1 expression.</li>
<li>58.8% ORR versus 49.2% ORR in patients with low PD-L1 expression.</li>
<li>47.4% ORR versus 32.3% ORR in patients with negative PD-L1.</li>
<li>In this all-comer PD-L1 trial, the 55.0% ORR and 87.5% Disease Control Rate (DCR) are from the following breakdown of patients by PD-L1 expression: high PD-L1 expression (N=4), low PD-L1 expression (N=17), and negative PD-L1 (N=19).</li>
<li>Compared to the general 1L NSCLC patient population, each of these PD-L1 levels represents roughly one-third, INSIGHT-003 is biased towards low and negative PD-L1 patients who are typically less responsive to anti-PD-1 therapy.</li>
<li>In these patients with low and negative PD-L1 expression (36 of 40 patients), the triple combination achieved a 52.8% ORR and 86.1% DCR.</li>
</ul>
INSIGHT-003, a multi-centre study led by the Frankfurt Institute of Clinical Cancer Research IKF, is nearing completion of patient enrolment.
Additional data updates from this trial are expected in 2025 and beyond.
Price Action: IMMP stock is up 9.6% at $2.05 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41970133/exclusive-adial-pharmaceuticals-reveals-topline-results-from-pharmacokinetics-study-of-ad04-for-alcohol-use-disorder" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Adial Pharmaceuticals Reveals Topline Results From Pharmacokinetics Study Of AD04 For Alcohol Use Disorder</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

Movers

General

IMMP

Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial

Nano Labs Ltd. Sponsored ADR Class A (NA) has released an update. Nano Labs' CEO, Mr. Jianping Kong, has demonstrated his confidence in the company...

Nano Labs CEO Bolsters Stake, Signaling Confidence

Nano Labs regains compliance with Nasdaq listing rule

Nano Labs Ltd. Sponsored ADR Class A (NA) has released an update. Nano Labs Ltd, a prominent fabless integrated circuit design company in China, ha...

Nano Labs Overcomes Nasdaq Market Value Hurdle

19:50 EDT Nano Labs (NA) Ltd trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breaking fin...

Nano Labs Ltd trading halted, news pending

Nano Labs starts to accept payments in Bitcoin

Nano Labs (NA) announced that the Company has set up a Coinbase account and starts accepting payments in Bitcoin in exchange for its products. This...

Nano Labs starts accepting payments in Bitcoin

Nano Labs Ltd. Sponsored ADR Class A (NA) has released an update. Nano Labs Ltd, a leading fabless integrated circuit design company, has begun acc...

Nano Labs Embraces Bitcoin to Enhance Global Transactions

Chinese microchip producer Nano Labs ($NA) may be the next big short squeeze, according to data from Fintel. The short analysis platform reports th...

Is Nano Labs (NASDAQ:NA) the Next Big Short Squeze?

09:41 EST Nano Labs (NA) Ltd trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. ...

Nano Labs Ltd trading resumes

09:31 EST Nano Labs (NA) Ltd trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-moving ...

Comments

Nano Labs

Nano Labs (NA) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル